Oliver Lagore Vanvalin Investment Group Sells 375 Shares of Boston Scientific Co. (NYSE:BSX)

Oliver Lagore Vanvalin Investment Group cut its stake in Boston Scientific Co. (NYSE:BSX) by 40.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 553 shares of the medical equipment provider’s stock after selling 375 shares during the quarter. Oliver Lagore Vanvalin Investment Group’s holdings in Boston Scientific were worth $43,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sierra Summit Advisors LLC purchased a new position in shares of Boston Scientific in the 4th quarter valued at $8,038,000. BI Asset Management Fondsmaeglerselskab A S increased its holdings in shares of Boston Scientific by 225.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after acquiring an additional 73,219 shares during the period. BDF Gestion purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $3,570,000. Precision Wealth Strategies LLC purchased a new position in shares of Boston Scientific in the 4th quarter valued at $956,000. Finally, Tlwm purchased a new position in shares of Boston Scientific in the 1st quarter valued at $927,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BSX has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft lifted their price target on Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a report on Thursday, July 25th. Barclays boosted their target price on Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Thursday, August 22nd. JPMorgan Chase & Co. boosted their target price on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. Robert W. Baird boosted their target price on Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Finally, Raymond James boosted their target price on Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, September 4th. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.65.

Insider Activity

In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the transaction, the executive vice president now owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 20,949 shares of company stock valued at $1,627,877 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $83.35 on Friday. The stock has a market cap of $122.28 billion, a PE ratio of 70.04, a price-to-earnings-growth ratio of 2.78 and a beta of 0.79. The business has a 50-day simple moving average of $79.33 and a 200-day simple moving average of $75.25. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $84.89.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.04. The business had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.53 EPS. On average, equities analysts expect that Boston Scientific Co. will post 2.4 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.